Current status and prospects of long-term albumin treatment in patients with cirrhotic ascites
DOI:10.3969/j.issn.1001-5256.2021.01.037
- VernacularTitle:肝硬化腹水患者长期应用白蛋白治疗的现状与前景
- Author:
Yu TIAN
1
;
Jia HONG
;
Bingqiong WANG
;
Hong YOU
Author Information
1. Liver Research Center, Beijing Friendship Hospital, Capital Medical University
- Publication Type:Research Article
- Keywords:
Liver Cirrhosis;
Ascites;
Serum Albumin
- From:
Journal of Clinical Hepatology
2021;37(1):173-175
- CountryChina
- Language:Chinese
-
Abstract:
At present, albumin is mainly used to prevent post-paracentesis circulatory dysfunction in patients with cirrhotic ascites, prevent renal dysfunction in patients with spontaneous peritonitis, and treat hepatorenal syndrome. Recent studies have shown that long-term albumin treatment can reduce the incidence rate of complications and improve overall prognosis in patients with cirrhotic ascites, which brings new insights into the indication for clinical application of albumin. This article reviews the clinical studies on the long-term administration of albumin in patients with cirrhotic ascites, aiming to provide evidence-based advice for further clinical research on long-term application of albumin in China.
